 Luminex Corporation NASDAQ: LMNX today announced that the Food and Drug Administration FDA has issued an Emergency Use Authorization EUA for the companys xMAP SARS-CoV-2 Multi-Antigen IgG Assay. Clinical laboratories can now use this serology assay to identify the presence of antibodies in people who have been infected with the virus that causes COVID-19. The test can be run on any of Luminexs xMAP-based high-throughput, gold-standard multiplex platforms, providing a more comprehensive and reliable assessment of immune response compared to conventional serology testing methods. 